Biomarkers
PD-L1 expression as a prognostic factor for postoperative outcomes in pleural mesothelioma
Translational Lung Cancer Research 2025 September 30 [Link] Masatoshi Kanayama, Takehiko Manabe, Katsuma Yoshimatsu, Yukiko Nemoto, Hiroki Matsumiya, Masataka Mori, Masaru Takenaka, Koji Kuroda, Fumihiro Tanaka Abstract Background: Pleural mesothelioma (PM) is an uncommon malignancy with a poor prognosis, even after surgical resection. Programmed death-ligand 1 (PD-L1) expression is a potential prognostic biomarker in various…
Read MoreDiscovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma
Lung Cancer 2025 September 28 [Link] Jasper H L T van Genugten, Daniel Faulkner, Jens C Hahne, Charlotte Poile, Lodewyk Wessels, Dean A Fennell, Paul Baas Abstract Background: Malignant pleural mesothelioma (PM) is an aggressive cancer with limited treatment options. Although first-line nivolumab plus ipilimumab improves outcomes for some patients, a majority fail to respond.…
Read MorePleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival
MedComm 2025 September 1 [Link] Libo Zhang, Meijuan Huang Abstract Pleural mesothelioma (PM) presents significant challenges in clinical management, with current treatment options such as chemotherapy, anti-angiogenic therapies, and immunotherapies only modestly extending progression-free survival (PFS) and overall survival (OS). Another relevant reason is the absence of subsequent-line therapy strategies following progression of PM after…
Read MoreCDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma
Journal of Experimental & Clinical Cancer Research 2025 August 28 [Link] Federica Torricelli, Benedetta Donati, Veronica Manicardi, Mila Gugnoni, Francesca Reggiani, Gloria Manzotti, Pierluigi Di Chiaro, Cristian Ascione, Simonetta Piana, Riccardo Valli, Roberto Piro, Massimiliano Paci, Nicola Facciolongo, Filippo Lococo, Alessia Ciarrocchi Abstract Introduction: Diffuse Pleural Mesothelioma (DPM) is a rare and incurable cancer. Immune…
Read MoreMulti-omics integration reveals CYTL1 and H6PD as key regulators of tumor metabolism in mesothelioma
Genes & Genomics 2025 August 25 [Link] Jiao Ma # 1, Huilin Zhang, Luanxue Yu, Yunqing Guo, Jiawei Ming, Zhenying Guo Abstract Background: Mesothelioma is a rare and aggressive cancer with limited therapeutic options and poor prognosis. Despite advancements in understanding its molecular mechanisms, effective biomarkers and therapeutic targets remain elusive. Objective: This study utilizes…
Read MorePrognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy
Immunotherapy 2025 August 20 [Link] Giulia Mazzaschi, Roberto Rosati, Simona D’Agnelli, Roberta Minari, Francesca Trentini, Prisca Tamarozzi, Martina Manini, Martina Zinelli Ronzoni, Alessandra Dodi, Letizia Gnetti, Lorena Bottarelli, Cinzia Azzoni, Gianmarco Martines, Monica Pluchino, Ilaria Toscani, Alessandro Leonetti, Fabiana Perrone, Paola Bordi, Giovanni Bocchialini, Luca Ampollini, Federico Quaini, Marcello Tiseo Abstract Aim: A translational multiscale…
Read MoreA Promising Prognostic Indicator for Pleural Mesothelioma: Pan-Immuno-Inflammation Value
Journal of Clinical Medicine 2025 August 4 [Link] Serkan Yaşar, Feride Yılmaz, Ömer Denizhan Tatar, Hasan Çağrı Yıldırım, Zafer Arık 1, Şuayib Yalçın, Mustafa Erman Abstract Background: Pleural mesothelioma (PM) is a type of cancer that is difficult to diagnose and treat. Patients may have vastly varying prognoses, and prognostic factors may help guide the…
Read MoreProspective Analysis of Mesotheliomas in Subjects with BAP1 Cancer Syndrome: Clinical Characteristics and Epigenetic Correlates of Disease
Journal of Thoracic Oncology 2025 August 5 [Link] Xinwei Wu, Frank-Villa Hernandez, Haitao Wang, Ruihong Wang, Stephanie Shiffka, Niharika Shah, Shamus R Carr, Chuong D Hoang, Andrew M Blakely, Alexandra Lebensohn, Keerti Mihsra, Sichuan Xi, Mary R Zhang, Tuana Tolunay, Sudheer Gara, Amanda Absher, Deneise Francis, Amanda Rowland, Maureen Connolly, Stephanie Jacobs, Sandra Orfgen, Kevin…
Read MoreSerum mesothelin as a response biomarker in pleural mesothelioma
Lung Cancer 2025 August [Link] Geraldine A Lynch, Jenny Symonds, Anna Morley, Emeka Azubuike-Dyer, Will Cooper, Anthony Edey, Duneesha De Fonseka, Selina Tsim Kevin Blyth Paul White, Nick A Maskell 5, Anna Bibby Abstract Background: CT scans are the current gold standard for disease monitoring for Pleural mesothelioma (PM), with radiology reported using the modified…
Read MoreSerum mesothelin as a response biomarker in pleural mesothelioma
Lung Cancer 2025 August [Link] Geraldine A Lynch, Jenny Symonds, Anna Morley, Emeka Azubuike-Dyer, Will Cooper, Anthony Edey, Duneesha De Fonseka, Selina Tsim, Kevin Blyth, Paul White, Nick A Maskell, Anna Bibby Abstract Background: CT scans are the current gold standard for disease monitoring for Pleural mesothelioma (PM), with radiology reported using the modified RECIST…
Read More
Skip to content